SC
ABEO icon

Sculptor Capital’s Abeona Therapeutics ABEO Stock Holding History

Sculptor Capital’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-336
Closed -$108K – 234
2018
Q3 		$108K Hold
336
– – ﹤0.01% 250
2018
Q2 		$134K Buy
+336
New +$147K ﹤0.01% 253

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Sculptor Capital's ABEO Position: Q4 2018 in Review

Sculptor Capital sold out of Abeona Therapeutics (ABEO) in Q4 2018, closing a stake of 336 shares — an estimated $108K sold.

Sculptor Capital first reported a position in ABEO in Q2 2018 and held it in 2 quarters. The position peaked at $134K in Q2 2018. 99 funds tracked by Wall St. Rank hold ABEO as of Q4 2018.

  • Sculptor Capital reported no remaining Abeona Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Sculptor Capital sold 336 Abeona Therapeutics shares in Q4 2018, an estimated $108K.
  • Sculptor Capital first reported a position in Abeona Therapeutics in Q2 2018 and held it in 2 quarters.
  • Sculptor Capital's Abeona Therapeutics position peaked at $134K in Q2 2018.
  • 99 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2018.

Based on Sculptor Capital's 13F filing for Q4 2018, filed 13 Feb 2019.